BHCM
LENZ

Brevan Howard Capital Management’s LENZ Therapeutics LENZ Stock Holding History

Brevan Howard Capital Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$124K Sell
13,570
-1,838
-12% -$25.8K ﹤0.01% 1990
2025
Q4 		$247K Buy
+15,408
New +$449K ﹤0.01% 1476

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Brevan Howard Capital Management's LENZ Position: Q1 2026 in Review

Brevan Howard Capital Management reduced its LENZ Therapeutics (LENZ) stake by 12% in Q1 2026, selling an estimated $25.8K and leaving 13,570 shares worth $124K. The position accounts for ﹤0.01% of the portfolio, ranked #1990.

Brevan Howard Capital Management first reported a position in LENZ in Q4 2025 and has held it in 2 quarters since. The position peaked at $247K in Q4 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • Brevan Howard Capital Management held 13,570 shares of LENZ Therapeutics worth $124K as of Q1 2026.
  • Brevan Howard Capital Management sold 1,838 LENZ Therapeutics shares in Q1 2026, an estimated $25.8K.
  • LENZ Therapeutics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1990 holding.
  • Brevan Howard Capital Management first reported a position in LENZ Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Brevan Howard Capital Management's LENZ Therapeutics position peaked at $247K in Q4 2025.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.